Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD
| Status: | Recruiting |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 50 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | February 2013 |
| End Date: | March 2016 |
| Contact: | Joseph Mastalski |
| Email: | mastalskijp@upmc.edu |
| Phone: | 412-683-7692 |
Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease
Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease
surrogate markers of bone metabolism and early cardiovascular disease in individuals with
moderate to severe airflow obstruction and a chronic bronchitis phenotype.
surrogate markers of bone metabolism and early cardiovascular disease in individuals with
moderate to severe airflow obstruction and a chronic bronchitis phenotype.
Inclusion Criteria:
- Subjects between the ages of 50 and 70 with a minimum of ten-pack years of tobacco
exposure, airflow obstruction (FEV1/FVC < 0.70) with an FEV1 < 70%
- baseline sputum production at least some of the time as reported on the Saint
George's Respiratory Questionnaire, and at least one exacerbation within the past
year
Exclusion Criteria:
- Subjects with chronic prednisone use, antiresorptive therapy use (bisphosphonates,
calcitonin, parathyroid hormone)
- Subjects with a body mass index less than 18 or greater than 34
We found this trial at
1
site
Click here to add this to my saved trials
